PLASMA ALPHA-1 ANTITRYPSIN LEVELS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS AT NGUYEN TRI PHUONG HOSPITAL

Hữu Ngọc Tuấn Nguyễn, Thị Thu Thảo Đào, Minh Hà Nguyễn

Main Article Content

Abstract

Background: Quantification of αlpha-1 antitrypsin (AAT) for early detection of chronic obstructive pulmonary disease (COPD) with reduced AAT. The plasma AAT level in Vietnamese patients has not been clarified. Objective: Characterization of plasma AAT concentration values in COPD patients at Nguyen Tri Phuong Hospital. Subjects and methods: a case series study, prospective sample collection, conveniently, on 70 patients diagnosed with COPD(GOLD 2022 criteria), at Nguyen Tri Phuong hospital, from 04/2022 to 08/2022. Plasma AAT levels were performed at the Laboratory Department of the hospital. Data is analyzed by using SPSS 20.0 software. Using the MannWhitney and KruskalWallis tests with a significant difference of p<0.05. Results: The 70 participants were most concentrated in the age group of 61-70 and mainly men. 95.7% had a diagnosis of COPD aged 40 years or older, 81.4% had active smoking, 26.7% had a history of asthma, 92.9% had no family history of COPD diagnosis, 91.5% had an FEV1/FVC < 0.7, and 40.4% had a 0.5 ≤ FEV1 < 0.8. The median plasma ATT level was 142.3 (128.3 – 156) mg/dL. There was no statistically significant difference in plasma AAT levels by age, sex, asthma history, family history, respiratory outcomes. There was an increase in plasma AAT levels in smokers compared with nonsmokers (p=0.017). Conclusion: plasma AAT levels in study subjects have been determined. Plasma AAT levels were initially determined to be significantly higher in the smoker group than in the non-smoking group.

Article Details

References

1. M. G. Foreman, M. Campos and J. C. Celedón (2012). Genes and chronic obstructive pulmonary disease. Med Clin North Am, 96(4), pp. 699-711.
2. R Gurvinder (2018), Alpha-1 Antitrypsin Deficiency. https://patient.info/chest-lungs/alpha-1-antitrypsin-deficiency-leaflet.
3. World Health Organization (2022), Bệnh phổi tắc nghẽn mãn tính ở Việt Nam, https:// www.who.int/vietnam/vi/health-topics/chronic-obstructive-pulmonary-disease-copd.
4. R. G. Edgar, et al. (2017). Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Int J Chron Obstruct Pulmon Dis, 12, pp. 1295-1308.
5. Global Initiative for Chronic Obstructive Lung Disease (2022). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/
6. M. Barrecheguren, et al. (2016). Diagnosis of alpha-1 antitrypsin deficiency: a population-based study. Int J Chron Obstruct Pulmon Dis, 11, pp. 999-1004.
7. S. Janciauskiene, et al. (2020). Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. Archivos de Bronconeumología, 56(2), pp. 76-83.
8. Linja-aho, et al. (2013). Distribution and levels of alpha-1-antitrypsin in the lung and plasma in smokers and chronic obstructive pulmonary disease. Apmis, 121(1), pp. 11-21.